LL 37

Drug Profile

LL 37

Alternative Names: LL-37

Latest Information Update: 30 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Karolinska Institute
  • Developer ProMore Pharma
  • Class Anti-infectives; Peptides
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Leg ulcer

Most Recent Events

  • 30 Sep 2016 Promore Pharma plans a phase IIb trial for Leg ulcer (Promore Pharma pipeline, September 2016)
  • 05 Jul 2016 Lipopeptide is now called ProMore Pharma
  • 15 Sep 2015 LL 37 is still in phase I/II development for venous leg ulcers in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top